Resveratrol induces ferroptosis in triple-negative breast cancer through NEDD4L-mediated GPX4 ubiquitination and degradation
- PMID: 40316059
- DOI: 10.1016/j.freeradbiomed.2025.04.052
Resveratrol induces ferroptosis in triple-negative breast cancer through NEDD4L-mediated GPX4 ubiquitination and degradation
Abstract
Triple-negative breast cancer (TNBC) has no expression on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), resulting in an ineffective treatment using current therapeutic therapies. As a heterogeneous disease, the notable refractory, high recurrence rate and unfavorable prognosis facilitate some researches to further elaborate novel insights into the biology of TNBC and formulate the precision treatment. Ferroptosis is a unique regulated-cell-death modality characterized by the excessive accumulation of the lipid peroxides on cellular membranes in an iron-dependent manner. Resveratrol (RES), a natural antioxidant that possesses biological activities, has various potential benefits for many diseases through regulating the cell activity. RES has been reported to markedly inhibit the tumor progression, yet its role in ferroptosis pathway of TNBC and the underlying mechanism remain unclear. In this study, we found that RES suppressed cell viabilities, consisting of cell migration, cell colony formation, and induced the cell apoptosis, along with mitochondrial structure damage, intracellular iron overload, increasing reactive oxygen species (ROS) and lipid peroxidation accumulation, malondialdehyde (MDA) production, and glutathione (GSH) depletion, interestingly, which was reversed by ferroptosis inhibitors. Next, the protein level of GPX4 was significantly suppressed in RES-treated TNBC cells in vitro and in vivo, facilitating the cancer cell ferroptosis. Our data confirm that RES suppresses GPX4 protein by increasing the NEDD4L-mediated ubiquitination attributed from the enhanced interactions between NEDD4L and GPX4 through the inhibition of the ERK1/2/SGK1/NEDD4L/GPX4 pathway in vitro and in vivo. In conclusion, our study identified the mechanism by which RES could exert ferroptosis in TNBC, finally providing a novel strategy for TNBC treatment.
Keywords: Ferroptosis; GPX4; NEDD4L; Resveratrol; Triple-negative breast cancer.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Nobiletin promotes ferroptosis in breast cancer through targeting AKR1C1-mediated ubiquitination and degradation of GPX4.Phytomedicine. 2025 Oct;146:157074. doi: 10.1016/j.phymed.2025.157074. Epub 2025 Jul 20. Phytomedicine. 2025. PMID: 40819642
-
α-Hederin causes ferroptosis in triple-negative breast cancer through modulating IRF1 to suppress GPX4.Phytomedicine. 2025 Jun;141:156611. doi: 10.1016/j.phymed.2025.156611. Epub 2025 Mar 8. Phytomedicine. 2025. PMID: 40153970
-
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.J Hematol Oncol. 2021 Jan 20;14(1):19. doi: 10.1186/s13045-020-01016-8. J Hematol Oncol. 2021. PMID: 33472669 Free PMC article.
-
Ferroptosis as a promising targeted therapy for triple negative breast cancer.Breast Cancer Res Treat. 2024 Oct;207(3):497-513. doi: 10.1007/s10549-024-07387-7. Epub 2024 Jun 14. Breast Cancer Res Treat. 2024. PMID: 38874688 Review.
-
GPX4 in triple-negative breast cancer: A key regulator of ferroptosis and therapeutic target.Cancer Genet. 2025 Sep;296-297:76-83. doi: 10.1016/j.cancergen.2025.06.009. Epub 2025 Jun 28. Cancer Genet. 2025. PMID: 40609246 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous